Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07530380) titled 'UCAR T-cell Therapy Targeting CD19/BCMA in Relapsed/Refractory Autoimmune Hemolytic Anemia' on April 8.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The Second Hospital of Anhui Medical University

Condition: AIHA - Warm Autoimmune Hemolytic Anemia UCART

Intervention: Biological: QT-219C Cell Injection

Recruitment Status: Recruiting

Phase: Early Phase 1

Date of First Enrollment: April 2026

Target Sample Size: 15

Countries of Recruitment: China

To know more, visit https://c...